Expert opinion by: Andrew Blumenfeld, MD, Director, The Headache Center of Southern California, 332 Santa Fe Drive, Encinitas, CA 92024, USA, email: blumenfeld@neurocenter.com
1526-4610/asset/olbannerleft.gif?v=1&s=21f1b7d4f2c4359aaf47df570ce3e86bae828611)
1526-4610/asset/olbannerright.gif?v=1&s=457ac636b692c34a480c656754b5858bd52359be)
OnabotulinumtoxinA for Chronic Migraine
Article first published online: 23 JAN 2012
DOI: 10.1111/j.1526-4610.2011.02071.x
© 2011 American Headache Society
Issue
Headache: The Journal of Head and Face Pain
Early View (Online Version of Record published before inclusion in an issue)
Additional Information
How to Cite
Blumenfeld, A. and Evans, R. W. (2012), OnabotulinumtoxinA for Chronic Migraine. Headache: The Journal of Head and Face Pain. doi: 10.1111/j.1526-4610.2011.02071.x
Case history by: Randolph W. Evans, MD, Baylor College of Medicine, 1200 Binz #1370, Houston, TX 77004, USA, email: rwevans@pol.net
Conflict of interest: Andrew Blumenfeld is a consultant and has received research grants from Allergan, Ipsen, and Mertz.
Publication History
- Article first published online: 23 JAN 2012
- Abstract
- Article
- References
- Cited By
First page of article
